Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Thyroid Eye Disease · Graves Orbitopathy · Endocrine System Diseases · Eye Diseases · Thyroid Associated Ophthalmopathy · Graves Ophthalmopathy · Thyroid Diseases · Orbital Diseases · Proptosis · IGF1R · Exophthalmos · Hashimoto

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Bascom Palmer Eye Institute, Miami, Florida, United States
Contact: Study coordinator (Jennifer Gomez) · jxg1540@miami.edu
West Virginia University Eye Institute, Morgantown, West Virginia, United States
Contact: Study coordinator (Athena Echols) · athena.sparks@wvumedicine.org

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease

Thyroid Eye Disease (TED)

Abroad (travel likely)RecruitingPHASE3

Shanghai, China

Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)

Thyroid Associated Ophthalmopathy

Abroad (travel likely)RecruitingPHASE3

Bangkok Noi, Thailand

Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease

Thyroid Eye Disease, TED · Graves Ophthalmopathy

Abroad (travel likely)Recruiting

Taipei, Taiwan